Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neurobiology of Disease

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NBD.2005.08.001PMID 16165367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

  2005cited by this paper
• Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease

  2005cited by this paper
• Characterization of striatal cultures with the effect of QUIN and NMDA.

  2004cited by this paper
• Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.

  2004cited by this paper
• Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.

  2004cited by this paper
• Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.

  2004cited by this paper
• Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-( 1 , 4 , 5 ) Triphosphate

  2003cited by this paper
• Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila.

  2003cited by this paper
• Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.

  2003cited by this paper
• Depletion of wild‐type huntingtin in mouse models of neurologic diseases

  2003cited by this paper
• Mitochondrial Dysfunction and Reactive Oxygen Species in Excitotoxicity and Apoptosis: Implications for the Pathogenesis of Neurodegenerative Diseases

  2003cited by this paper
• Are Huntington's and polyglutamine-based ataxias proteasome storage diseases?

  2003cited by this paper
• Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

  2003cited by this paper
• Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.

  2003cited by this paper
• Calcium-dependent Cleavage of Endogenous Wild-type Huntingtin in Primary Cortical Neurons*

  2002cited by this paper
• Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease

  2002cited by this paper
• Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

  2002cited by this paper
• Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32.

  2002cited by this paper
• Calpain Activation in Huntington's Disease

  2002cited by this paper
• Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

  2002cited by this paper
• Mitochondrial permeability transition and calcium dynamics in striatal neurons upon intense NMDA receptor activation

  2002cited by this paper
• Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

  2001cited by this paper
• Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis

  2001cited by this paper
• Cortical and striatal neuronal cultures of the same embryonic origin show intrinsic differences in glutamate receptor expression and vulnerability to excitotoxicity.

  2001cited by this paper
• NMDA receptor function in mouse models of Huntington disease

  2001cited by this paper
• Loss of normal huntingtin function: new developments in Huntington's disease research.

  2001cited by this paper
• Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.

  2001cited by this paper
• A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease

  2001cited by this paper
• Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons.

  2000cited by this paper
• Transcriptional dysregulation in Huntington's disease.

  2000cited by this paper
• A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

  1999cited by this paper
• Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization

  1999cited by this paper
• Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.

  1999cited by this paper
• Mitochondrial Depolarization Is Not Required for Neuronal Apoptosis

  1999cited by this paper
• Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels.

  1999cited by this paper
• Cellular Localization of Huntingtin in Striatal and Cortical Neurons in Rats: Lack of Correlation with Neuronal Vulnerability in Huntington’s Disease

  1999cited by this paper
• Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin

  1999cited by this paper
• Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease.

  1999cited by this paper
• The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity

  1998cited by this paper
• Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates

  1998cited by this paper
• Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors.

  1998cited by this paper
• Distinct Influx Pathways, Not Calcium Load, Determine Neuronal Vulnerability to Calcium Neurotoxicity

  1998cited by this paper
• Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons.

  1998cited by this paper
• Neuronal cell death: an updated view.

  1998cited by this paper
• Huntington disease.

  1998cited by this paper
• Chapter 1 Neuronal cell death: An updated view

  1998cited by this paper
• Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract*

  1998cited by this paper
• Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

  1997cited by this paper
• Ca2+ and Reactive Oxygen Species in Staurosporine‐Induced Neuronal Apoptosis

  1997cited by this paper
• Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

  1997cited by this paper
• Expression of NMDA receptor-1 (NR1) and huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study.

  1997cited by this paper
• Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

  1997cited by this paper
• Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

  1997cited by this paper
• The effects of artificial calcium buffers on calcium responses and glutamate-mediated excitotoxicity in cultured hippocampal neurons.

  1997cited by this paper
• Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype.

  1996cited by this paper
• Mitochondrial defect in Huntington's disease caudate nucleus

  1996cited by this paper
• Staurosporine-induced neuronal apoptosis.

  1995cited by this paper
• Induction of a common pathway of apoptosis by staurosporine.

  1994cited by this paper
• GABA synapses formed in vitro by local axon collaterals of nucleus accumbens neurons

  1994cited by this paper
• Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

  1992cited by this paper
• Alternative excitotoxic hypotheses

  1992cited by this paper
• Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease.

  1990cited by this paper
• The quinolinic acid model of Huntington's disease: locomotor abnormalities.

  1989cited by this paper
• Differential loss of striatal projection neurons in Huntington disease.

  1988cited by this paper
• NMDA receptor losses in putamen from patients with Huntington's disease.

  1988cited by this paper
• Morphologic and Histochemical Characteristics of a Spared Subset of Striatal Neurons in Huntington's Disease

  1987cited by this paper
• Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

  1986cited by this paper
• Neuropathological Classification of Huntington's Disease

  1985cited by this paper

• Multi‐Omic Analysis of Glutamate Excitotoxicity in Primary Neuronal Cultures

  2025cites this paper
• Significance of NMDA receptor-targeting compounds in neuropsychological disorders: An In-depth Review.

  2025cites this paper
• SerpinA3N inhibits mitochondrial complex I activity to prevent neuron ferroptosis following cerebral ischemic stroke.

  2025cites this paper
• Huntingtin Decreases Susceptibility to a Spontaneous Seizure Disorder in FVN/B Mice

  2023cites this paper
• Various facets of excitotoxicity

  2022cites this paper
• Structural Plasticity of the Hippocampus in Neurodegenerative Diseases

  2022cites this paper
• Power Failure of Mitochondria and Oxidative Stress in Neurodegeneration and Its Computational Models

  2021cites this paper
• Chronic and Acute Manipulation of Cortical Glutamate Transmission Induces Structural and Synaptic Changes in Co-cultured Striatal Neurons

  2021cites this paper
• C57BL/6 Background Attenuates mHTT Toxicity in the Striatum of YAC128 Mice

  2021cites this paper
• Poly-arginine-18 (R18) Confers Neuroprotection through Glutamate Receptor Modulation, Intracellular Calcium Reduction, and Preservation of Mitochondrial Function

  2020cites this paper
• Thalamostriatal degeneration contributes to dystonia and cholinergic interneuron dysfunction in a mouse model of Huntington’s disease

  2020cites this paper
• A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2

  2020cites this paper
• Mitochondrial SIRT3 confers neuroprotection in Huntington's disease by regulation of oxidative challenges and mitochondrial dynamics.

  2020cites this paper
• Homeostatic plasticity in neuronal cultures from the YAC128 Huntington disease model mouse

  2019cites this paper
• Proteomic analysis of cortical neuronal cultures treated with poly-arginine peptide-18 (R18) and exposed to glutamic acid excitotoxicity

  2019cites this paper
• Activation of caspase‐6 and cleavage of caspase‐6 substrates is an early event in NMDA receptor–mediated excitotoxicity

  2018cites this paper
• The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease

  2018cites this paper
• Molecular and Synaptic Alterations in the Striatum of GluN1-Deficient Mice

  2018cites this paper
• The adjustment of γ-aminobutyric acidA tonic subunits in Huntington's disease: from transcription to translation to synaptic levels into the neostriatum

  2018cites this paper
• 20 Don ’ t Take Away My P : Phosphatases as Therapeutic Targets in Huntington ’ s Disease

  2018cites this paper
• Huntington’s Disease: Calcium Dyshomeostasis and Pathology Models

  2017cites this paper
• Succinate dehydrogenase: Prospect for neurodegenerative diseases.

  2017cites this paper
• Cellular calcium signaling in the aging brain.

  2017cites this paper
• Alterations of Synaptic Function in Huntington's Disease

  2017cites this paper
• Mitochondrial Ca2+ handling in Huntington's and Alzheimer's diseases - Role of ER-mitochondria crosstalk.

  2017influential citation
• Tetrahydrocarbazoles decrease elevated SOCE in medium spiny neurons from transgenic YAC128 mice, a model of Huntington's disease.

  2017cites this paper
• Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.

  2016cites this paper
• Impact of caspase-6 modulation on Huntington disease phenotypes in the YAC128 mouse model

  2016cites this paper
• The Influence of Na+, K+-ATPase on Glutamate Signaling in Neurodegenerative Diseases and Senescence

  2016cites this paper
• Corticostriatal Dysfunction in Huntington’s Disease: The Basics

  2016cites this paper
• Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington’s Disease

  2016influential citation
• Glutamate Signaling in Neurodegenerative Diseases and Senescence

  2016cites this paper
• Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model

  2016cites this paper
• Brain metabolism as a modulator of autophagy in neurodegeneration.

  2016cites this paper
• Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington’s Disease

  2015cites this paper
• How the manipulation of the Ras homolog enriched in striatum alters the behavioral and molecular progression of Huntington's disease

  2015cites this paper
• Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?

  2015cites this paper
• Alterations of Thalamostriatal and Corticostriatal Projections in Mouse Models of Huntington’s Disease

  2015cites this paper
• Rosiglitazone Synergizes the Neuroprotective Effects of Valproic Acid Against Quinolinic Acid-Induced Neurotoxicity in Rats: Targeting PPARγ and HDAC Pathways

  2014cites this paper
• Novel osmotin attenuates glutamate-induced synaptic dysfunction and neurodegeneration via the JNK/PI3K/Akt pathway in postnatal rat brain

  2014cites this paper
• Differential Changes in Postsynaptic Density Proteins in Postmortem Huntington's Disease and Parkinson's Disease Human Brains

  2014cites this paper
• Alterations in STriatal‐Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model

  2014cites this paper
• Altered Ca 2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington’s disease

  2014cites this paper
• [Huntington's disease: cellular and molecular basis of pathology].

  2014cites this paper
• Altered Ca2+ signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington’s disease

  2014cites this paper
• Autophagy and apoptosis dysfunction in neurodegenerative disorders.

  2014cites this paper
• Voltage-dependent calcium signaling in muscle fibers of mouse models of neuromuscular disorders

  2013cites this paper
• Estudo do Efeito Neuroprotetor do Eugenol em Modelo Experimental da Doença de Huntington

  2013cites this paper
• Adenosine Receptors in Huntington’s Disease

  2013cites this paper
• Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors

  2013cites this paper
• The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

  2012cites this paper
• Opposing Roles of Synaptic and Extrasynaptic NMDA Receptor Signaling in Cocultured Striatal and Cortical Neurons

  2012cites this paper
• Don’t Take Away My P: Phosphatases as Therapeutic Targets in Huntington’s Disease

  2012cites this paper
• Dysregulation of Mitochondrial Calcium Signaling and Superoxide Flashes Cause Mitochondrial Genomic DNA Damage in Huntington Disease*

  2012cites this paper
• Hippocampal Glutamate Level and Glutamate Aspartate Transporter (GLAST) are Up-Regulated in Senior Rat Associated with Isoflurane-Induced Spatial Learning/Memory Impairment

  2012cites this paper
• Mouse Models of Polyglutamine Diseases: Review and Data Table. Part I

  2012cites this paper
• Scaffolding Proteins of the Post-synaptic Density Contribute to Synaptic Plasticity by Regulating Receptor Localization and Distribution: Relevance for Neuropsychiatric Diseases

  2012cites this paper
• Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.

  2012cites this paper
• Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.

  2012cites this paper
• Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo

  2012cites this paper
• Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities.

  2012cites this paper
• Role of CaMKII and the GluN2B subunit of the NMDAR in dorsal striatal glutamatergic synaptic transmission, MSN morphology and striatal-based behaviors

  2012cites this paper
• Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke

  2012cites this paper
• Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease.

  2012cites this paper
• INVESTIGATING THE MECHANISM OF PROMOTER-SPECIFIC N-TERMINAL MUTANT HUNTINGTIN-MEDIATED TRANSCRIPTIONAL DYSREGULATION

  2012cites this paper
• HUNTINGTON DISEASE: CURRENT ADVANCES IN PATHOGENESIS AND RECENT THERAPEUTIC STRATEGIES

  2011cites this paper
• Innovative approaches to monitor mutant huntingtin and to facilitate its degradation in Huntington's disease models

  2011cites this paper
• Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines

  2011cites this paper
• Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease.

  2011cites this paper
• Pathogenic mechanisms in Huntington's disease.

  2011cites this paper
• Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.

  2011cites this paper
• Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

  2011cites this paper
• Signaling pathways involved in enhanced NMDA receptor-dependent excitotoxicity in a mouse model of Huntington disease

  2011cites this paper
• Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--memantine.

  2011cites this paper
• Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

  2011cites this paper
• Pharmacokinetics of memantine in rats and mice

  2011cites this paper
• Synaptic Dysfunction in Huntington’s Disease

  2011cites this paper
• Pharmacokinetics of memantine in rats and mice.

  2011cites this paper
• Testing of neuroprotective compounds in a transgenic mouse model of Huntington's disease

  2011cites this paper
• Transgenic Animal Models of Huntington's Disease.

  2011cites this paper
• Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.

  2010cites this paper
• Calcium Signaling and Neurodegeneration

  2010cites this paper
• Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice.

  2010influential citation
• Phosphorylation of Huntingtin at Ser421 in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A

  2010cites this paper
• Tetrabenazine is neuroprotective in Huntington's disease mice

  2010cites this paper
• Peripheral and cerebral metabolic features in an animal model of Huntington's disease

  2010cites this paper
• In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons

  2010cites this paper
• Molecular and cellular mechanisms of excitotoxic neuronal death

  2010cites this paper
• Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease.

  2010cites this paper
• Estudio de las vías de supervivencia y muerte neuronal en modelos de la enfermedad de Huntington

  2010cites this paper
• N‐Methyl‐d‐aspartate receptor subunit‐ and neuronal‐type dependence of excitotoxic signaling through post‐synaptic density 95

  2010influential citation
• DifferentialSusceptibilitytoExcitotoxicStressinYAC128 MouseModelsofHuntingtonDiseasebetweenInitiationand ProgressionofDisease

  2009cites this paper
• A Novel Pathophysiological Gene-Environment Interaction Suppresses the Neurotoxic Activities of (Mn) and Mutant HD

  2009cites this paper
• NMDA Receptors and Huntington’s Disease

  2009cites this paper
• Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease

  2009cites this paper
• Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease

  2009cites this paper
• Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

  2009cites this paper
• Ginsenosides protect striatal neurons in a cellular model of Huntington's disease

  2009cites this paper
• Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.

  2009cites this paper
• Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease

  2009cites this paper